The 12 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 53.50, with a high estimate of 66.00 and a low estimate of 17.00. The median estimate represents a +29.92% increase from the last price of 41.18.
The current consensus among 12 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.43
Reporting Date Nov 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.